Navigation Links
Once-Daily Combo Works for New HIV Patients
Date:8/2/2008

Tazanavir/ritonavir as good as twice-daily dose of lopinavir/ritonavir, study says

FRIDAY, Aug. 1 (HealthDay News) -- Once-daily treatment with tazanavir/ritonavir (A/R) is as effective as twice-daily treatment with lopinavir/ritonavir (L/R) in HIV patients who are starting antiretroviral treatment for the first time, a European study shows.

Based on their findings, the researchers recommended once-daily A/R as a first-line treatment option for treatment-naive HIV patients since it has a number of advantages over the currently recommended twice-daily L/R.

The study included 883 treatment-naive HIV patients who were randomly assigned to receive A/R 300/100 milligrams once daily (440 patients) or L/R 400/100 milligrams twice daily (443 patients). Both regimens were in combination with tenofovir/emtricitabine 300/200 once daily, as is standard.

After 48 weeks of treatment, 78 percent of patients receiving A/R and 76 percent of those receiving L/R had a viral load of less than 50 copies per milliliters in their blood, and both groups showed similar increases in the numbers of immune system CD4 cells. Six percent of patients in both groups failed on the treatments, and two patients in the A/R group developed resistance mutations to treatment, compared with none in the L/R group.

Serious side effects were reported in 12 percent of the A/R patients and 10 percent of the L/R patients, but fewer A/R patients experienced treatment-related diarrhea (2 percent vs. 11 percent) and nausea (4 percent vs. 8 percent). None of the L/R patients developed jaundice, which occurred in 4 percent of A/R patients.

"In treatment-naive patients, atazanavir/ritonavir once-daily demonstrated similar antiviral efficacy to lopinavir/ritonavir twice daily, with less gastrointestinal toxicity but with a higher rate of hyperbilirubinaemia...the results of this study support the use of once-daily atazanavir/ritonavir as a recommended first-line treatment option, with a number of patient benefits over the currently recommended ritonavir-boosted twice-daily lopinavir for the treatment of HIV-infected antiretroviral-naive patients," the researchers concluded.

The study appears online in The Lancet, and was expected to be published in an upcoming print edition of the journal.

More information

The American Academy of Family Physicians has more about HIV medicines.



-- Robert Preidt



SOURCE: The Lancet, news release, Aug. 2, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Labopharms Once-Daily Tramadol Product Launched in South Korea, Australia, Romania and Austria
2. New Data Highlights Positive Results of Namenda (Memantine HCl) Once-Daily Extended-Release Formulation
3. FDA accepts Labopharms response for once-daily tramadol as complete Class 2 response
4. Labopharm Reaquires UK Sales And Marketing Rights to Its Once-Daily Tramadol Product
5. Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol
6. Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
7. FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults
8. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
9. Once-Daily Insulin Shot Proves Effective in Study
10. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
11. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: